FMP
Medifast, Inc.
MED
NYSE
Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products in the United States and the Asia-Pacific. The company offers bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serves, shakes, smoothies, soft bakes, and soups under the OPTAVIA, Optimal Health by Take Shape for Life, and Flavors of Home brands. It markets its products through point-of-sale transactions over ecommerce platform. The company was founded in 1980 and is headquartered in Baltimore, Maryland.
12.38 USD
-0.54 (-4.36%)
Historical Prices
From:
To:
About
ceo
Mr. Daniel R. Chard
sector
Consumer Cyclical
industry
Personal Products & Services
website
https://medifastinc.comexchange
NYSE
Description
Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products in the United States and the Asia-Pacific. The company offers bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serves, shakes, smoothies, soft bakes, and soups under the OPTAVIA, Optimal Health by Take Shape for Life, and Flavors of Home brands. It markets its products through point-of-sale transactions over ecommerce platform. The company was founded in 1980 and is headquartered in Baltimore, Maryland.
CIK
0000910329
ISIN
US58470H1014
CUSIP
58470H101
Address
100 International Drive
Phone
410 581 8042
Country
US
Employee
504
IPO Date
Dec 30, 1993
Financial Statement
Earnings
MED Financial Summary
CIK
0000910329
Exchange
NYSE
Industry
Personal Products & ...
Sector
Consumer Cyclical
CUSIP
58470H101
ISIN
US58470H1014
Country
US
Price
12.38
Beta
1.08
Volume Avg.
230.02k
Market Cap
135.41M
Shares
-
52-Week
12.275-36.3
DCF
501.46
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
65.16
P/B
-
Website
https://medifastinc.com
Upgrades and Downgrades
We are unable to load the data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest MED News
Danny Green
Feb 5, 2025
Medexus Pharmaceuticals' Financial Performance and Strategic...
Medexus Pharmaceuticals, trading under the symbol MEDXF on the PNK exchange, is a specialty pharmaceutical company focused on the development and commercialization of innovative and rare disease treatments. The company competes with other pharmaceutical firms in the niche market of rare diseases. On February 5, 2025, Medexus reported earnings per share (EPS) of $0.03, surpassing the estimated $0.02, showcasing its ability to exceed market expectations. Despite the positive EPS, Medexus generate...
Tony Dante
Feb 5, 2025
Medexus Pharmaceuticals Quarterly Earnings Overview
Medexus Pharmaceuticals, trading under the symbols TSX: MDP and OTCQX: MEDXF, is a specialty pharmaceutical company. It focuses on the acquisition and distribution of innovative pharmaceutical products across North America. The company is set to release its quarterly earnings on February 5, 2025, with analysts estimating an earnings per share of $0.02 and projected revenue of $40.8 million. The company has scheduled a conference call for February 6, 2025, to discuss its financial results for th...
Rayan Ahmad
Nov 4, 2024
Medifast, Inc. (NYSE:MED) Surpasses Market Expectations with...
Medifast, Inc. (NYSE:MED) is a company known for its weight loss and health management products. It operates in the health and wellness industry, competing with companies like Nutrisystem and Weight Watchers. On November 4, 2024, MED reported its quarterly earnings, showcasing a strong performance that exceeded market expectations. MED reported earnings per share (EPS) of $0.1029, surpassing the estimated loss of $0.28. This achievement is notable, especially when compared to the Zacks Consensu...
Zacks Investment Research
Aug 26, 2024
Medifast's (MED) Strategies Aid Amid Evolving Market Demands
Medifast (MED) is making efforts to thrive in the rapidly evolving weight loss market, as the adoption of GLP-1 medications reshapes industry dynamics.
Zacks Investment Research
Aug 14, 2024
Medifast (MED) Tumbles 25% in 3 Months: Should You Buy Now?
Medifast (MED) is encountering difficulties in attracting customers due to a reduction in the number of active OPTAVIA Coaches and diminished productivity per Coach.
Zacks Investment Research
Aug 6, 2024
Medifast (MED) Q2 Earnings Beat Estimates, Revenues Fall Y/Y
Medifast's (MED) Q2 results highlight the challenges of poor customer acquisition. However, the company is focusing strategically on medically supported weight loss, indicating potential for growth.
Seeking Alpha
Aug 5, 2024
Medifast, Inc. (MED) Q2 2024 Earnings Call Transcript
Medifast, Inc. (NYSE:MED ) Q2 2024 Earnings Conference Call August 5, 2024 4:30 PM ET Company Participants Steven Zenker - Vice President, Investor Relations Dan Chard - Chairman and Chief Executive Officer Jim Maloney - Chief Financial Officer Conference Call Participants James Salera - Stephens Linda Bolton-Weiser - D.A. Davidson David Larsen - BTIG Operator And welcome to the Medifast Second Quarter 2024 Earnings Conference Call.
Zacks Investment Research
Aug 5, 2024
Medifast (MED) Q2 Earnings and Revenues Beat Estimates
Medifast (MED) came out with quarterly earnings of $0.92 per share, beating the Zacks Consensus Estimate of $0.36 per share. This compares to earnings of $2.77 per share a year ago.
